Regeneron Pharmaceuticals (LTS:0R2M) EBIT per Share : $43.69 (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regeneron Pharmaceuticals EBIT per Share?

Regeneron Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2024 was $12.97. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $43.69.

During the past 12 months, the average EBIT per Share Growth Rate of Regeneron Pharmaceuticals was -8.20% per year. During the past 3 years, the average EBIT per Share Growth Rate was 6.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 18.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was 24.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Regeneron Pharmaceuticals's EBIT per Share or its related term are showing as below:

LTS:0R2M' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -121.7 Med: 15.5 Max: 53.7
Current: 6.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Regeneron Pharmaceuticals was 53.70% per year. The lowest was -121.70% per year. And the median was 15.50% per year.

LTS:0R2M's 3-Year EBIT Growth Rate is ranked better than
54.65% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs LTS:0R2M: 6.20

Regeneron Pharmaceuticals's EBIT for the three months ended in Sep. 2024 was $1,507 Mil.

Regeneron Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Regeneron Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals EBIT per Share Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

21.46

33.60

83.63

43.33

37.58

Regeneron Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															9.95	10.25	6.23	14.24	12.97

Regeneron Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Regeneron Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	4272.3	/	113.700
=	37.58

Regeneron Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1506.8	/	116.200
=	12.97

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.69

Regeneron Pharmaceuticals (LTS:0R2M) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Regeneron Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (LTS:0R2M) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines